The Society for Immunotherapy of Cancer (SITC) published the first Clinical Practice Guideline (CPG) on immunotherapy for the treatment of Cutaneous Melanoma in Nature Reviews Clinical Oncology in 2013.On May 30, 2018, SITC published an update in the Journal for ImmunoTherapy of Cancer (JITC), the society's open access, peer-reviewed online journal. Since the 2018 publication, the therapeutic landscape has continued to evolve, with FDA approvals for pembrolizumab in the adjuvant setting as well as atezolizumab in combination with BRAF/MEK inhibition for advanced disease. To assist clinicians in incorporating these and other advances into practice, SITC is currently developing a new CPG with topics including selection of appropriate immunotherapeutic regimens, recognition and management of adverse events, and patient quality of life considerations.The SITC Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for patients with cancer. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure a fair, transparent and balanced process for creating the CPGs. Each CPG expert panel is comprised of a balanced group including academic physicians and researchers, nurses, patients, and patient advocates. The guidelines are reviewed on an ongoing basis to account for newly available clinical trial data and FDA approvals. Each expert panel addresses knowledge gaps in general understanding of the optimal clinical use of immunotherapy to offer practical, actionable recommendations to help cancer care providers develop immunotherapy treatment plans for their patients.
Published May 30, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0."Updated July 27, 2018 Current treatment algorithms for the SITC Cancer Immunotherapy Guidelines - Cutaneous Melanoma.
SITC is pleased to offer free webinars featuring Expert Panel members from SITC's Cutaneous Melanoma Immunotherapy Guideline. These educational offerings are designed for healthcare providers who treat cancer patients including oncologists, physicians, disease specialists, registered nurses, nurse practitioners, pharmacists and physician assistants. The live webinars include a dedicated question-and-answer session providing the opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations. SITC is pleased to offer companion educational resources in support of the published Cutaneous Melanoma CPG. These activities feature faculty comprised of the guideline expert panel and are designed to provide a deeper understanding of the recommendations in the SITC guidelines and how to apply them in various clinical scenarios. The educational available features both webinars which are a longer-format recording that takes a deeper look at the guideline recommendations as well as mini-modules which are brief videos on a specific topic within the guideline content. Below is a list of the available educational resources for this CPG available free and on-demand.Webinars:
*This webinar has no external funding sources.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com